Steinberg, Gregory R.
Hardie, D. Grahame http://orcid.org/0000-0002-8373-7379
Article History
Accepted: 23 September 2022
First Online: 31 October 2022
Competing interests
: D.G.H. declares no competing interests. G.R.S. has received research funding from Esperion Therapeutics, Espervita Therapeutics, Poxel Pharmaceuticals, Nestle, Novo Nordisk and Rigel Pharmaceuticals; honoraria and/or consulting fees from AstraZeneca, Cambrian BioPharma, EcoR1 Capital, Eli-Lilly, Esperion Therapeutics, Fibrocor Therapeutics, Pfizer, Poxel Pharmaceuticals and Merck; and is a founder and shareholder of Espervita Therapeutics.